Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387009079> ?p ?o ?g. }
- W4387009079 endingPage "13" @default.
- W4387009079 startingPage "1" @default.
- W4387009079 abstract "Parkinson's disease (PD) is a complex syndrome with many elements, such as chronic inflammation, oxidative stress, mitochondrial dysfunction, loss of dopaminergic neurons, build-up of alpha-synuclein (α-syn) in cells, and energy depletion in neurons, that drive the disease. We and others have shown that treatment with mimetics of the growth factor glucagon-like peptide 1 (GLP-1) can normalize energy utilization, neuronal survival, and dopamine levels and reduce inflammation. Liraglutide is a GLP-1 analogue that recently showed protective effects in phase 2 clinical trials in PD patients and in Alzheimer disease patients. We have developed a novel dual GLP-1/GIP receptor agonist that can cross the blood-brain barrier and showed good protective effects in animal models of PD. Here, we test liraglutide against the dual GLP-1/GIP agonist DA5-CH (KP405) in the A53T tg mouse model of PD which expresses a human-mutated gene of α-synuclein. Drug treatment reduced impairments in three different motor tests, reduced levels of α-syn in the substantia nigra, reduced the inflammation response and proinflammatory cytokine levels in the substantia nigra and striatum, and normalized biomarker levels of autophagy and mitochondrial activities in A53T mice. DA5-CH was superior in almost all parameters measured and therefore may be a better drug treatment for PD than liraglutide." @default.
- W4387009079 created "2023-09-26" @default.
- W4387009079 creator A5003607548 @default.
- W4387009079 creator A5007760639 @default.
- W4387009079 creator A5026427905 @default.
- W4387009079 creator A5049854957 @default.
- W4387009079 creator A5067359249 @default.
- W4387009079 creator A5073318338 @default.
- W4387009079 creator A5073618545 @default.
- W4387009079 creator A5078740664 @default.
- W4387009079 creator A5079916185 @default.
- W4387009079 creator A5082707086 @default.
- W4387009079 creator A5082917352 @default.
- W4387009079 date "2023-09-25" @default.
- W4387009079 modified "2023-10-14" @default.
- W4387009079 title "A Dual GLP-1/GIP Receptor Agonist Is More Effective than Liraglutide in the A53T Mouse Model of Parkinson’s Disease" @default.
- W4387009079 cites W1012070930 @default.
- W4387009079 cites W1527671059 @default.
- W4387009079 cites W1965095016 @default.
- W4387009079 cites W1974898145 @default.
- W4387009079 cites W1974924674 @default.
- W4387009079 cites W1975774284 @default.
- W4387009079 cites W1979237351 @default.
- W4387009079 cites W1979591162 @default.
- W4387009079 cites W1983434420 @default.
- W4387009079 cites W1986216002 @default.
- W4387009079 cites W1990366009 @default.
- W4387009079 cites W1996611755 @default.
- W4387009079 cites W2011284760 @default.
- W4387009079 cites W2022847635 @default.
- W4387009079 cites W2039542458 @default.
- W4387009079 cites W2042613656 @default.
- W4387009079 cites W2050581000 @default.
- W4387009079 cites W2053725882 @default.
- W4387009079 cites W2063980028 @default.
- W4387009079 cites W2065165825 @default.
- W4387009079 cites W2068288454 @default.
- W4387009079 cites W2068495410 @default.
- W4387009079 cites W2073279468 @default.
- W4387009079 cites W2075793841 @default.
- W4387009079 cites W2080785707 @default.
- W4387009079 cites W2081619699 @default.
- W4387009079 cites W2082425146 @default.
- W4387009079 cites W2084521532 @default.
- W4387009079 cites W2084948079 @default.
- W4387009079 cites W2090012352 @default.
- W4387009079 cites W2092791231 @default.
- W4387009079 cites W2097965815 @default.
- W4387009079 cites W2112292567 @default.
- W4387009079 cites W2124122508 @default.
- W4387009079 cites W2129917779 @default.
- W4387009079 cites W2130213256 @default.
- W4387009079 cites W2131222480 @default.
- W4387009079 cites W2139084760 @default.
- W4387009079 cites W2145044522 @default.
- W4387009079 cites W2145399920 @default.
- W4387009079 cites W2149284026 @default.
- W4387009079 cites W2149717292 @default.
- W4387009079 cites W2150472993 @default.
- W4387009079 cites W2161461930 @default.
- W4387009079 cites W2168440171 @default.
- W4387009079 cites W2199406275 @default.
- W4387009079 cites W2211963426 @default.
- W4387009079 cites W2317095451 @default.
- W4387009079 cites W2468864843 @default.
- W4387009079 cites W2528242093 @default.
- W4387009079 cites W2559570574 @default.
- W4387009079 cites W2584311212 @default.
- W4387009079 cites W2593866083 @default.
- W4387009079 cites W2599792256 @default.
- W4387009079 cites W2744843428 @default.
- W4387009079 cites W2745164635 @default.
- W4387009079 cites W2770385888 @default.
- W4387009079 cites W2785903681 @default.
- W4387009079 cites W2791252329 @default.
- W4387009079 cites W2804862081 @default.
- W4387009079 cites W2807256450 @default.
- W4387009079 cites W2809697129 @default.
- W4387009079 cites W2887342138 @default.
- W4387009079 cites W2908881986 @default.
- W4387009079 cites W2913876135 @default.
- W4387009079 cites W2924479779 @default.
- W4387009079 cites W2941817107 @default.
- W4387009079 cites W2955403065 @default.
- W4387009079 cites W2978840913 @default.
- W4387009079 cites W2987466500 @default.
- W4387009079 cites W2991554614 @default.
- W4387009079 cites W2996654920 @default.
- W4387009079 cites W3000000012 @default.
- W4387009079 cites W3001146304 @default.
- W4387009079 cites W3006657664 @default.
- W4387009079 cites W3013242926 @default.
- W4387009079 cites W3019350328 @default.
- W4387009079 cites W3046853160 @default.
- W4387009079 cites W3092981856 @default.
- W4387009079 cites W3118579634 @default.
- W4387009079 cites W3128241185 @default.
- W4387009079 cites W3135159820 @default.